Progresses in DNA-Based Heterologous Prime-Boost Immunization Strategies

Methods in Molecular Biology

Volumn 1143, Issue , 2014, Pages 61-90

  Jackson, Ronald J ^a   Boyle, David B ^a   Ranasinghe, Charani ^a  

^a NONE

Author keywords

DNA vaccines; Fowlpox virus; Homing marker analysis; Intracellular cytokine staining; Mucosal systemic cell preparation; Mucosal systemic vaccination; Poxvirus vectors; Prime boost immunization; T cell immunity; Tetramer analysis; Vaccinia virus

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; DNA VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; FIBROBLAST; FOWLPOX VIRUS; HOMOLOGOUS RECOMBINATION; IMMUNIZATION; MOUSE; NONHUMAN; POXVIRIDAE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ELECTROPHORESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VACCINIA VIRUS; ZINC FINGER MOTIF; ADMINISTRATION AND DOSAGE; ANIMAL; CHICK EMBRYO; CULTURE TECHNIQUE; GENE VECTOR; GENETICS; HUMAN; IMMUNOLOGY; VACCINATION;

ANIMALS; CELL CULTURE TECHNIQUES; CHICK EMBRYO; GENETIC VECTORS; HUMANS; IMMUNITY, CELLULAR; IMMUNIZATION, SECONDARY; MICE; POXVIRIDAE; VACCINATION; VACCINES, DNA; VACCINIA VIRUS;

EID: 84907536541     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4939-0410-5_5     Document Type: Article

References (39)

1. Leong KH, Ramsay AJ, Boyle DB et al (1994) Selective induction of immune responses by cytokines coexpressed in recombinant fowlpox virus. J Virol 68:8125–8130
2. Ramsay AJ, Husband AJ, Ramshaw IA et al (1994) The role of interleukin-6 in mucosal IgA antibody responses in vivo. Science 264: 561–563
3. Kent SJ, Zhao A, Best SJ et al (1998) Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus. J Virol 72:10180–10188
4. Hanke T, Samuel RV, Blanchard TJ et al (1999) Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen. J Virol 73:7524–7532
5. Amara RR, Villinger F, Altman JD et al (2001) Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292:69–74
6. Stambas J, Brown SA, Gutierrez A et al (2005) Long lived multi-isotype anti-HIV antibody responses following a prime-double boost immunization strategy. Vaccine 23:2454–2464
7. Metcalf D, Begley CG, Johnson GR et al (1986) Effects of purified bacterially synthesized murine multi-CSF (IL-3) on hematopoiesis in normal adult mice. Blood 68:46–57
8. Kelleher AD, Puls RL, Bebbington M et al (2006) A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1. AIDS 20:294–297
9. Hemachandra A, Puls RL, Sirivichayakul S et al (2010) An HIV-1 clade A/E DNA prime, recombinant fowlpox virus boost vaccine is safe, but non-immunogenic in a randomized phase I/IIa trial in Thai volunteers at low risk of HIV infection. Hum Vaccin 6:835–840
10. McCormack S, Stohr W, Barber T et al (2008) EV02: A Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime- NYVAC-C boost to NYVAC-C alone. Vaccine 26:3162–3174
11. Sekaly RP (2008) The failed HIV Merck vaccine study: A step back or a launching point for future vaccine development? J Exp Med 205: 7–12
12. Ranasinghe C, Turner SJ, McArthur C et al (2007) Mucosal HIV-1 pox virus prime-boost immunization induces high-avidity CD8+ T cells with regime-dependent cytokine/granzyme B profiles. J Immunol 178:2370–2379
13. Gomez CE, Najera JL, Jimenez EP et al (2007) Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B. Vaccine 25:2863–2885
14. Esteban M (2009) Attenuated poxvirus vectors MVA and NYVAC as promising vaccine candidates against HIV/AIDS. Hum Vaccin 5: 867–871
15. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S et al (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361:2209–2220
16. Yuan Z, Chen W, Zhang J et al (2012) Development of an immunoassay for differentiating human immunodeficiency virus infections–from vaccine-induced immune response in Tiantan vaccine trials in China. Clin Biochem 45:1219–1224
17. Kent SJ, Dale CJ, Ranasinghe C et al (2005) Mucosally-administered human-simian immunodeficiency virus DNA and fowlpoxvirusbased recombinant vaccines reduce acute phase viral replication in macaques following vaginal challenge with CCR5-tropic SHIVSF162P3. Vaccine 23:5009–5021
18. Ranasinghe C, Medveczky JC, Woltring D et al (2006) Evaluation of fowlpox-vaccinia virus prime-boost vaccine strategies for high-level mucosal and systemic immunity against HIV-1. Vaccine 24:5881–5895
19. Ranasinghe C, Ramshaw IA (2009) Immunisation route-dependent expression of IL-4/IL-13 can modulate HIV-specific CD8(+) CTL avidity. Eur J Immunol 39:1819–1830
20. Ranasinghe C, Eyers F, Stambas J et al (2011) A comparative analysis of HIV-specific mucosal/ systemic T cell immunity and avidity following rDNA/rFPV and poxvirus-poxvirus prime boost immunisations. Vaccine 29: 3008–3020
21. Ranasinghe C, Trivedi S, Stambas J et al (2013) Unique IL-13Ralpha2-based HIV-1 vaccine strategy to enhance mucosal immunity, CD8(+) T-cell avidity and protective immunity. Mucosal Immunol 6(6):1068–1080. doi: 10.1038/mi.2013.1
22. Green MR, Sambrook J (2012) Molecular cloning: A laboratory manual, 4th edn. Cold Spring Harbor Laboratory Press, Spring Harbor, NY
23. Coupar BE, Andrew ME, Boyle DB (1988) A general method for the construction of recombinant vaccinia viruses expressing multiple foreign genes. Gene 68:1–10
24. Heine HG, Boyle DB (1993) Infectious bursal disease virus structural protein VP2 expressed by a fowlpox virus recombinant confers protection against disease in chickens. Arch Virol 131:277–292
25. Coupar BE, Purcell DF, Thomson SA et al (2006) Fowlpox virus vaccines for HIV and SHIV clinical and pre-clinical trials. Vaccine 24:1378–1388
26. Dale CJ, Thomson S, De Rose R et al (2006) Prime-boost strategies in DNA vaccines. Methods Mol Med 127:171–197
27. Boyle DB, Anderson MA, Amos R et al (2004) Construction of recombinant fowlpox viruses carrying multiple vaccine antigens and immunomodulatory molecules. Biotechniques 37(104–106):108–111
28. Ranasinghe C, Trivedi S, Stambas J et al (2013) Unique IL-13Rα2 based HIV-1 vaccine strategy to enhance mucosal immunity, CD8+ T cell avidity and protective immunity. Mucosal Immunol 6(6):1068–1080
29. Kozak M (1987) An analysis of 5′-noncoding sequences from 699 vertebrate messenger RNAs. Nucleic Acids Res 15:8125–8148
30. Coupar BE, Andrew ME, Both GW et al (1986) Temporal regulation of influenza hemagglutinin expression in vaccinia virus recombinants and effects on the immune response. Eur J Immunol 16:1479–1487
31. Townsend A, Bastin J, Gould K et al (1988) Defective presentation to class I-restricted cytotoxic T lymphocytes in vaccinia-infected cells is overcome by enhanced degradation of antigen. J Exp Med 168:1211–1224
32. Earl PL, Moss B (2001) Characterization of recombinant vaccinia viruses and their products. Curr Protoc Mol Biol 43:16.18.11– 16.18.11
33. Earl PL, Moss B, Wyatt LS et al (2001) Generation of recombinant vaccinia viruses. Curr Protoc Mol Biol 43:16.17.11–16.17.19
34. Earl PL, Cooper N, Wyatt LS et al (2001) Preparation of cell cultures and vaccinia virus stocks. Curr Protoc Mol Biol 43:16.16.11–16.16.13
35. Buller RM, Smith GL, Cremer K et al (1985) Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype. Nature 317:813–815
36. Andrew ME, Coupar BE, Boyle DB (1989) Humoral and cell-mediated immune responses to recombinant vaccinia viruses in mice. Immunol Cell Biol 67:331–337
37. Listvanova S, Temmerman S, Stordeur P et al (2003) Optimal kinetics for quantification of antigen-induced cytokines in human peripheral blood mononuclear cells by real-time PCR and by ELISA. J Immunol Methods 281:27–35
38. Day SL (2008) Evaluation of interferon responses and activity for effective vaccine therapy. Ph.D., Australian National University
39. Trivedi S, Jackson RJ, Ranasinghe C (2012) Interleukin-3 and granulocyte-macrophage colony- stimulating factor expression, a biomarker of memory CD8+ T cell immunity and vaccine efficacy. J Vaccines Vaccination 3:166–173